Today: 16 March 2026
Subscribe
Browse Category

LSE:WKP 19 November 2025

FTSE 100’s Record Run: Inside London’s Blue-Chip Rally and What’s Next

London Stock Market Outlook for 20 November 2025: Key Things to Know Before the FTSE 100 Opens

The FTSE 100 closed down 0.4–0.5% on Wednesday, marking its fifth straight loss and hitting a four-week low near 9,500. Aerospace, defence, and bank stocks led declines, while energy shares fell with oil prices. UK October inflation slowed to 3.6%, prompting markets to price in a December Bank of England rate cut with over 80% probability. Sterling and gilt yields slipped after the data.
19 November 2025
··········

Stock Market Today

  • JNJ's Bladder Cancer Therapy Erda-iDRS Hits Primary Safety Endpoint in Early-Stage Trial
    March 16, 2026, 2:59 PM EDT. Johnson & Johnson's (JNJ) investigational bladder cancer treatment, Erda-iDRS, met its primary safety endpoint in a Phase I study targeting non-muscle-invasive bladder cancer (NMIBC) with FGFR gene alterations, found in up to 70% of intermediate-risk and 40% of high-risk patients. The localized drug-delivery system releases erdafitinib directly into the bladder, limiting systemic side effects. Results showed an 89% complete response (CR) rate in intermediate-risk patients, with median CR duration around 18 months. High-risk patients saw median recurrence-free survival of 20 months and 83% survival at 12 months. The therapy was generally well-tolerated with mild to moderate adverse effects and no dose-limiting toxicities. Shares of JNJ rose 36.3% over six months, outperforming the 17.2% industry gain, as the company prepares for further development steps.
Go toTop